On Friday, Shares of Intrexon Corp (NYSE:XON), gained 0.44% to $41.34.
Intrexon Corporation the closing of its formerly declared public offering of common stock, counting the exercise in full by the underwriters of their option to purchase an additional 731,707 shares of common stock at the public offering price of $41.00 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by Intrexon to 5,609,756 shares and raised the total gross proceeds raised in the offering to about $230 million, before deducting the underwriting discounts, commissions, and estimated expenses.
JMP Securities LLC acted as sole book-running manager for the offering. Stifel acted as lead manager for the offering. Griffin Securities and Wunderlich Securities acted as co-managers for the offering.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
At the end of Friday’s trade, Shares of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO), gained 0.11% to $35.61.
Carrizo Oil & Gas declared that administration is planned to present at the following forthcoming conference.
Barclays CEO Energy-Power Conference, on Wednesday, September 9, 2015 at 12:25 pm EDT, New York, NY.
Carrizo Oil & Gas, Inc., together with its auxiliaries, engages in the exploration, development, and production of oil and gas primarily in the United States. The company holds interests in crude oil plays and projects, counting Eagle Ford Shale in Texas; the Niobrara Formation located in Colorado; the Utica Shale in Ohio; and the Marcellus Shale located in Pennsylvania.
Finally, Authentidate Holding Corp. (NASDAQ:ADAT), ended its last trade with 22.90% gain, and closed at $0.344.
Authentidate Holding declared the first cross-sold application of Authentidate’s leading telehealth solutions and AEON Clinical Laboratory’s leading clinical solutions. As declared on August 25, 2015, Authentidate and AEON Clinical Laboratories have reached a non-binding letter of intent to combine.
Authentidate will provide its HIPAA-compliant telehealth platform to AEON Clinical Laboratory, an expanding clinical laboratory. The initial implementation will be rolled out to eight Houston-area clinics, with upwards of 80,000 patients, to deliver remote mental health and rehab treatment. The program is ultimately predictable to be expanded to 160 clinics. Outpatient reimbursement averages from $6,000-$8,000 per patient, per month. With the first eight clinics, AEON anticipates to treat 10,000 patients annually, and treatment duration to be one month.
Authentidate Holding Corp. provides Web-based software applications, and telehealth products and services in the United States. The company offers Inscrybe Healthcare, a secure Web-based workflow automation solution that enables healthcare industry participants to exchange and track various documents, certificates, authorizations, and other information in various modes of communication, such as electronic and fax delivery; Inscrybe Office, a Web-based service to sign, seal, and confirm receipt of documents over the Web for business or personal use; and AuthentiProof, a content integrity and time-and-date stamp application to verify the authenticity of a document or file sent electronically.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
